Search hospitals > Louisiana > Marrero

West Jefferson Medical Center

Claim this profile
Marrero, Louisiana 70072
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Brain Tumor
30 reported clinical trials
5 medical researchers
Photo of West Jefferson Medical Center in MarreroPhoto of West Jefferson Medical Center in MarreroPhoto of West Jefferson Medical Center in Marrero

Summary

West Jefferson Medical Center is a medical facility located in Marrero, Louisiana. This center is recognized for care of Lung Cancer, Breast cancer, Breast Cancer, Ovarian Cancer, Brain Tumor and other specialties. West Jefferson Medical Center is involved with conducting 30 clinical trials across 104 conditions. There are 5 research doctors associated with this hospital, such as Brian C. Boulmay, Augusto C. Ochoa, Tara Castellano, and Amelia Jernigan, MD.

Area of expertise

1Lung Cancer
West Jefferson Medical Center has run 7 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
PD-L1 positive
Stage III
2Breast Cancer
West Jefferson Medical Center has run 7 trials for Breast cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at West Jefferson Medical Center

Ovarian Cancer
Uterine Cancer
Breast cancer
Breast Cancer
Cancer
Endometrial Adenocarcinoma
Meningioma
Colon Cancer
Endometrial Cancer
Uterine Carcinosarcoma
Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Recruiting2 awards Phase 34 criteria
Image of trial facility.

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at West Jefferson Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security